Cytokinetics (CYTK) Tops Q3 EPS by 7c
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $80.18 -0.22%
Revenue Growth %: -74.4%
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
UBAB, LOAN, FITB, More
Revenue Growth %: -74.4%
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
UBAB, LOAN, FITB, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $7.9 million versus the consensus estimate of $11.24 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
- DB cautious on cruise stocks as fundamentals “not as clear as bulls believe”
- Meritage Hospitality posts Q2 loss amid restructuring charges
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
